Spec­trum shares crater as first round of piv­otal da­ta for their TKI falls short of pri­ma­ry end­point

Spec­trum Phar­ma­ceu­ti­cals had been talk­ing up its chances of get­ting an ac­cel­er­at­ed ap­proval for their EGFR TKI pozi­o­tinib for non-small cell lung can­cer off of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER